WO2009011420A1 - Agent thérapeutique pour le diabète de type 2 - Google Patents
Agent thérapeutique pour le diabète de type 2 Download PDFInfo
- Publication number
- WO2009011420A1 WO2009011420A1 PCT/JP2008/063008 JP2008063008W WO2009011420A1 WO 2009011420 A1 WO2009011420 A1 WO 2009011420A1 JP 2008063008 W JP2008063008 W JP 2008063008W WO 2009011420 A1 WO2009011420 A1 WO 2009011420A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- type
- therapeutic agent
- diabetes
- act
- liver
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
- C07J9/005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane containing a carboxylic function directly attached or attached by a chain containing only carbon atoms to the cyclopenta[a]hydrophenanthrene skeleton
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Engineering & Computer Science (AREA)
- Emergency Medicine (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Steroid Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
L'invention porte sur un agent médicinal comprenant de l'acide ursodésoxycholique ou un sel pharmaceutiquement acceptable de celui-ci en tant qu'ingrédient actif, qui peut agir en tant qu'agent thérapeutique pour le diabète de type-2 accompagné d'une stéatose hépatique ou d'un dysfonctionnement du foie.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2009523682A JPWO2009011420A1 (ja) | 2007-07-18 | 2008-07-18 | 2型糖尿病の治療薬 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2007186430 | 2007-07-18 | ||
JP2007-186430 | 2007-07-18 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2009011420A1 true WO2009011420A1 (fr) | 2009-01-22 |
Family
ID=40259746
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2008/063008 WO2009011420A1 (fr) | 2007-07-18 | 2008-07-18 | Agent thérapeutique pour le diabète de type 2 |
Country Status (2)
Country | Link |
---|---|
JP (1) | JPWO2009011420A1 (fr) |
WO (1) | WO2009011420A1 (fr) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2567959A1 (fr) | 2011-09-12 | 2013-03-13 | Sanofi | Dérivés d'amide d'acide 6-(4-Hydroxy-phényl)-3-styryl-1H-pyrazolo[3,4-b]pyridine-4-carboxylique en tant qu'inhibiteurs |
WO2013041519A1 (fr) * | 2011-09-19 | 2013-03-28 | ETH Zürich, ETH Transfer | Modulateurs de ror gamma |
CN115137732A (zh) * | 2021-03-29 | 2022-10-04 | 中国科学院大连化学物理研究所 | Gpr120受体激动剂及熊去氧胆酸的应用 |
-
2008
- 2008-07-18 JP JP2009523682A patent/JPWO2009011420A1/ja active Pending
- 2008-07-18 WO PCT/JP2008/063008 patent/WO2009011420A1/fr active Application Filing
Non-Patent Citations (7)
Title |
---|
BONDINI, S. ET AL.: "Non-alcoholic fatty liver disease and hepatitis C infection", MINERVA GASTROENTEROL DIETOL, vol. 52, no. 2, 2006, pages 135 - 143, XP002663026 * |
ITOH, S. ET AL.: "Combined treatment with ursodeoxycholic acid and pioglitazone in a patient with NASH associated with type 2 diabetes and psoriasis", DIG DIS SCI, vol. 48, no. 11, 2003, pages 2182 - 2186 * |
LINDOR, K.D. ET AL.: "Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: Results of a randomized trial", HEPATOLOGY, vol. 39, no. 3, 2004, pages 770 - 778, XP002663026 * |
MARCHESINI, G. ET AL.: "Nonalcoholic fatty liver disease and the metabolic syndrome", MINERVA CARDIOANGIOL, vol. 54, no. 2, 2006, pages 229 - 239 * |
OZCAN, U. ET AL.: "Chemical chaperones reduce ER stress and restore glucose homeostasis in a mouse model of type 2 diabetes", SCIENCE, vol. 313, August 2006 (2006-08-01), pages 1137 - 1140, XP002674360 * |
SASS, D.A. ET AL.: "Nonalcoholic fatty liver disease: a clinical review", DIG DIS SCI, vol. 50, no. 1, 2005, pages 171 - 180, XP019237111 * |
TOLMAN, K.G. ET AL.: "Spectrum of liver disease in type 2 diabetes and management of patients with diabetes and liver disease", DIABETES CARE, vol. 30, no. 3, March 2006 (2006-03-01), pages 734 - 743, XP055354115 * |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2567959A1 (fr) | 2011-09-12 | 2013-03-13 | Sanofi | Dérivés d'amide d'acide 6-(4-Hydroxy-phényl)-3-styryl-1H-pyrazolo[3,4-b]pyridine-4-carboxylique en tant qu'inhibiteurs |
WO2013041519A1 (fr) * | 2011-09-19 | 2013-03-28 | ETH Zürich, ETH Transfer | Modulateurs de ror gamma |
KR20140079416A (ko) * | 2011-09-19 | 2014-06-26 | 에테하 쭈리히 | Ror 감마 모듈레이터 |
AU2012311599B2 (en) * | 2011-09-19 | 2017-07-06 | Eth Zurich | Ror gamma modulators |
RU2658013C2 (ru) * | 2011-09-19 | 2018-06-19 | Этх Цюрих | Модуляторы ror-гамма |
KR102020923B1 (ko) | 2011-09-19 | 2019-09-11 | 에테하 쭈리히 | Ror 감마 모듈레이터 |
CN115137732A (zh) * | 2021-03-29 | 2022-10-04 | 中国科学院大连化学物理研究所 | Gpr120受体激动剂及熊去氧胆酸的应用 |
Also Published As
Publication number | Publication date |
---|---|
JPWO2009011420A1 (ja) | 2010-09-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2010122980A8 (fr) | Nouvel agoniste du récepteur ss de l'hormone thyroïdienne | |
WO2010136474A3 (fr) | Dérivés aminobutyriques substitués en tant qu'inhibiteurs de néprilysine | |
WO2011051354A3 (fr) | Compositions pharmaceutiques transdermiques contenant des agents actifs | |
WO2009085990A3 (fr) | Procédés de préparation de sitagliptine et sels pharmaceutiquement acceptables de celle-ci | |
EP2196206B8 (fr) | Remède destiné à soulager des troubles cutanés comprenant un dérivé de morphinane ou l'un de ses sels d'addition d'acide acceptables sur le plan pharmacologique en tant que principe actif | |
WO2005089718A3 (fr) | Compositions pharmaceutiques | |
IL195269A0 (en) | Pharmaceutical formulations for the sustained release of active ingredient(s), as well as their applications, especially therapeutic | |
WO2008096001A8 (fr) | Phénylcarbamates macrocycliques inhibant le virus de l'hépatite c (vhc) | |
WO2011066980A3 (fr) | Formes de dose orale avec risque réduit d'abus de médicaments | |
WO2009051119A1 (fr) | Composé de pyrimidylindoline | |
WO2009004082A3 (fr) | Compositions pharmaceutiques anticonvulsives | |
WO2009041663A1 (fr) | Agent destiné à la prévention et/ou au traitement de maladies cutanées | |
PL1932522T3 (pl) | Środek terapeutyczny do leczenia choroby wątroby zawierający jako składnik czynny pochodną 2-amino-1,3-propanodiolu | |
EP2045253A4 (fr) | DÉRIVÉ D'ACIDE alpha-AMINÉ ET PRODUIT PHARMACEUTIQUE QUI LE COMPREND EN TANT QUE MATIÈRE ACTIVE | |
WO2010130773A3 (fr) | Dérivés de benzoxazolone en tant qu'inhibiteurs d'aldostérone synthase | |
TN2012000092A1 (en) | Therapeutic agent for mood disorders | |
MY163762A (en) | Therapeutic agent for chronic renal failure | |
WO2012140596A8 (fr) | Dérivés de glycoside et leurs utilisations | |
WO2009038412A3 (fr) | Composés inhibiteurs de la béta-sécrétase | |
WO2008129501A3 (fr) | Compositions pharmaceutiques de duloxetine | |
IL201418A0 (en) | Therapeutic agent for glaucoma containing adenosine derivative as active ingredient | |
WO2009051223A1 (fr) | Composition pharmaceutique pour le traitement de la cataracte | |
EP2316420A8 (fr) | Procédé pour réduire la douleur | |
WO2008068299A3 (fr) | Sel de bromhydrate d'un composé anti-vih | |
WO2011047837A3 (fr) | Cinacalcet granulé par fusion |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 08791317 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2009523682 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 08791317 Country of ref document: EP Kind code of ref document: A1 |